Biomarkers associated with checkpoint inhibitors - Archive ouverte HAL Access content directly
Journal Articles Annals of Oncology Year : 2016

Biomarkers associated with checkpoint inhibitors


Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Fichier principal
Vignette du fichier
Biomarkers Associated with Checkpoint Inhibitors.pdf (862.91 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-01359396 , version 1 (07-10-2016)



G. Manson, J. Norwood, A. Marabelle, H. Kohrt, R. Houot. Biomarkers associated with checkpoint inhibitors. Annals of Oncology, 2016, 27 (7), pp.1199--1206. ⟨10.1093/annonc/mdw181⟩. ⟨hal-01359396⟩
748 View
401 Download



Gmail Facebook Twitter LinkedIn More